Introduction
As non-valvular atrial fibrillation (AF) confers an increased risk of stroke and systemic embolism, guidelines recommend oral anticoagulation (OAC) to reduce this risk 1 . However, OAC also brings an increased risk of major bleeding, such as gastrointestinal and intracranial haemorrhage (ICH). The concept of net clinical benefit (NCB) has been used to quantify the balance between a reduced risk of stroke and systemic embolism compared to an increased risk of ICH with OAC in the setting of stroke prevention in patients with AF. Indeed, patients at highest risk of stroke and systemic embolism gain the greatest benefit from OAC 2 .
The risk of stroke and systemic embolism in AF is not homogeneous, but depends upon the presence of certain clinical factors, alone or in combination. Major stroke risk factors have been combined to give the CHADS 2 (Chronic heart failure, Hypertension, Age >75 years, Diabetes mellitus (all 1 point), Stroke or transient ischaemic attack (2 points)) and CHA 2 DS 2 -VASc (Chronic heart failure, Hypertension, Age >75 years (2 points), Diabetes mellitus, Stroke, systemic embolism or transient ischaemic attack (2 points), Vascular disease, Age 65-74, Sex category i.e. female) scores 3, 4 . Both scores are used to assess the risk of stroke and systemic embolism in AF, and incorporated to guidelines for risk stratification 1 . The use of OAC is also associated with bleeding (including ICH), and once more, certain risk factors have been used to develop the HAS-BLED (Hypertension, Abnormal liver/renal function, prior Stroke/thromboembolism, Bleeding tendency, Labile international normalised ratio,
Elderly (e.g. age over 65 years), Drugs (e.g. concomitant use of aspirin or NSAIDs, or alcohol excess) score for bleeding risk stratification 6 .
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ACCEPTED MANUSCRIPT 5 The vitamin K antagonists (VKAs, e.g. warfarin) have traditionally been the only available OAC. More recently, several non-VKA oral anticoagulants (NOACs) have shown favourable efficacy and safety results, compared with warfarin [7] [8] [9] [10] . Of these NOACs, the oral factor Xa inhibitor edoxaban, at low and high doses of 30 mg or 60 mg (respectively) once daily, was found to be non-inferior to warfarin in protecting against stroke and systemic embolism in AF, and was associated with significantly less ICH, major bleeding and death from cardiovascular causes than warfarin 10 .
Highly structured randomised controlled trials of NOACs may fail to translate to a 'real world' population, where the value of these agents also needs to be determined and compared with that of a VKA. In data from the .
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Methods

Study population
The cohort used in this model was patients with non-valvular AF from the Danish National 11 . Treatment periods were determined for each patient by dividing the number of tables dispensed with the estimated daily dosage, a method described in detail previously and which allows the patient to be considered as at risk only during treatment periods [13] [14] [15] . These data were compared with those from the ENGAGE AF-TIMI 48 trial of edoxaban
Model assumptions
The event rates per 100 person-years for ischaemic stroke and systemic embolism and major bleeding (ICH, gastrointestinal bleeding, bleeding from the urinary tract, etc.) were calculated using data from the Danish nationwide cohort study population for patients on no treatment with and on warfarin, stratified by stroke risk as predicted by their CHADS 2 and CHA 2 DS 2 VASc scores 11 . Using the modified intention to treat primary end points of stroke and systemic embolic event data (table 2) , and the ICH data (table 3) of the ENGAGE AF study 10 , the equivalent event rates were estimated for the Danish population. For this model, the 'real world' hazard ratios of the sum of stroke and systemic embolic event with edoxaban compared to warfarin were taken to be 0.79 for edoxaban 60 mg od and 1.07 for edoxaban 30 mg od. The 'real world' hazard ratios of ICH with edoxaban compared to warfarin were assumed to be 0.47 for edoxaban 60 mg od and 0.26 for edoxaban 30 mg od 10 . The relative risks of stroke, systemic embolic event and ICH were assumed to be constant across all categories of thrombosis risk and bleeding risk.
The number of patients needed to treat (NNT) to prevent one ischaemic stroke and systemic embolism per year was calculated as the reciprocal of the absolute risk reduction (i.e.
1/ARR)
, that is, the event rate on no treatment minus the event rate on treatment 12 . NNTs were also calculated for ICH with a negative value denoting the 'number needed to harm'
(NNH) 12 , that is, the number of patients treated in order to cause one ICH. The NCB of each anticoagulant compared with no treatment was calculated using the formula: (stroke and systemic embolism rate on no treatment minus stroke and systemic embolism rate on anticoagulant) -1.5 (ICH rate on anticoagulant minus ICH rate on no treatment) 2 . The
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8 weighting of 1.5 reflects the relative impact, in terms of death and disability, of an ICH. NNTs and NNHs are adjusted for a one-year period. Table 1 shows the event rates for stroke and systemic embolism per 100 patient years, and classified according to risk. In order to estimate the rates of stroke and systemic embolism whilst taking edoxaban, we multiplied the hazard ratios from the ENGAGE trial 10 events/100 patient-years) and NNT of 232 patients was equivalent to that of warfarin, but was higher than that of edoxaban 60 mg. For both anticoagulants the event rates were greater with increasing CHADS 2 and CHA 2 DS 2 -VASc scores. NNTs for those on edoxaban and warfarin were lower with increasing scores. 12 . These data translate to warfarin causing one ICH per 714 patients treated in a year (i.e. a NNH of -714). In order to estimate the rates of ICH whilst taking edoxaban, we multiplied the hazard ratios for ICH from the ENGAGE trial 10 with the rates of ICH from the Danish cohort 12 . In this model, both doses of edoxaban had significantly lower adjusted Table 3 presents the NCB of warfarin and edoxaban when compared with no treatment.
Results
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NCB of warfarin and edoxaban when compared with no treatment
Warfarin use is associated with a reduced rate of stoke and systemic embolism ( In considering risk profiles with the CHADS 2 and CHA 2 DS 2 -VASc scores, differences emerge.
At all CHADS 2 scores, and CHA 2 DS 2 -VASc score 2-9, warfarin has a positive NCB compared to no treatment, but at CHA 2 DS 2 -VASc scores 0 and 1, warfarin has no positive benefit over no treatment. At all CHADS 2 and CHA 2 DS 2 -VASc scores, both doses of edoxaban have superior NCB values than no treatment. At CHADS 2 scores 0 and 1, the two edoxaban doses bring similar NCBs compared to each other, and are superior to no treatment [ Table 3 ], but at CHADS 2 2-6, the 60 mg dose had a better NCB than the 30mg dose or warfarin. At CHA 2 DS 2 -VASc scores 0 and 1, both doses of edoxaban had marginally positive NCBs compared to no treatment, but the 30mg dose had superior NCBs than the 60 mg dose. At CHA 2 DS 2 -VASc
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10 score 2-9, the 60 mg dose had a better NCB than the 30 mg dose or warfarin. For both OACs, NCBs increased with increasing CHADS 2 and CHA 2 DS 2 -VASc scores. superior NCBs than warfarin, and was similar for the two edoxaban doses. These results are illustrated in figure 1 .
NCB for edoxaban 30 mg and 60 mg compared with warfarin
Sensitivity analysis
We performed a further analysis based on the likelihood that the rate of ICH were twice that observed in the trial, and that the rate of stroke and systemic embolism were lowered by 50%. Results presented in supplementary When using an OAC in AF patients, the benefit of a reduction in the risk of a thrombotic event such as stroke and systemic embolisation must be weighed against the risk of major bleeding such as ICH. However, the risk of stroke and thromboembolism in an individual varies markedly according to the sum of certain risk factors. As we previously reported 11, 12 , the NCB is only negative with warfarin at a CHA 2 DS 2 -VASc score 0 or 1, reflecting the 'truly low risk' status of these patients. In our model for the present study, without risk factor stratification, both doses of edoxaban are predicted to result in lower rates of both types of events (thrombotic and haemorrhagic, and so equivalent NCBs) compared with warfarin.
Our prediction that a NOAC brings a reduction of over 50% in the risk of ICH in a real world database is entirely in line with a recent meta-analysis 16 . However, these data assume each risk regardless of concurrent clinical and demographic features.
Classifying stroke risk by the CHADS 2 method, at low and moderate risk of stroke, both doses of edoxaban provide similar improved NCB over warfarin. At the high risk of stroke, high-dose (60 mg) edoxaban is superior to both low dose (30 mg) edoxaban and warfarin.
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The CHA 2 DS 2 -VASc system recognises a limitation inherent in CHADS 2 , in that the latter places more patients at low risk of stroke than the former, potentially denying treatment to some 4 . This is borne out by data indicating that at low CHA 2 DS 2 -VASc scores of 0 and 1, when compared to no treatment, warfarin causes more harm than good whereas at a CHADS 2 score of 0, the use of warfarin can be justified in some patients. At a low and moderate CHA 2 DS 2 -VASc risk of stroke (scores 0 and 1), edoxaban 30 mg provides more benefit than edoxaban 60 mg, whereas at high risk (CHA 2 DS 2 -VASc score 2-9), edoxaban 60 mg is preferred.
Practitioners and patients alike fear haemorrhage, the risk of which can be determined by the HAS-BLED score 5 . When risk of bleeding is low (HAS-BLED score <2), our modelling data predict that edoxaban 30 mg is the preferred dose regardless of stroke risk, except when defined by CHADS 2 2-6, where the two doses bring equivalent benefit. Patients with a high HAS-BLED score (≥3), and a low risk of stroke according to CHADS 2 (score 1) or a moderate risk of stroke according CHA 2 DS 2 -VASc (score 1) will benefit equally from any oral anticoagulant. Due to low numbers of patients and events, our analyses of CHA 2 DS 2 VASc score 0 and high bleeding risk may be unreliable. Patients at high risk of stroke according to CHADS 2 score 2-6 or CHA 2 DS 2 VASc score 2-9 gain the same benefit from either dose of edoxaban. The NCB data are broadly comparable with those of other NOACs, which have NCBs between 0.58 and 3.76 events prevented/100 patient-years 12 .
Limitations
We note several limitations of this analysis. Our model calls for merging of data from a formal clinical trial 10 with that from a community population 11 , two groups who may differ in clinical profiles. Indeed, we assume the relative risk observed in a RCT would be similar to
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13 the one happening in the real-world population, which may be an oversimplification;
indeed, patients in RCTs are generally not representative of the general population and therefore, the risks that are observed in RCTs cannot be assumed to be the same in the 'real world' population. In addition, other models have been used, so results may be different.
Accordingly, there may be error in the estimates of the effects of edoxaban compared to warfarin. The mean (standard deviation) CHADS 2 score in the ENGAGE AF-TIMI 48 trial was 2.8 (1.0) 10 , that for the Danish cohort 11 is estimated to be perhaps 1.25 (0.8), indicating that the latter are at considerably less risk of stroke. Furthermore, we cannot determine the degree of warfarin anticoagulation control in the two groups and assume they are equal: it is possible that INR control is less rigorous in the community and this may impact on outcomes 17, 18 . Furthermore, since warfarin doses vary frequently, we acknowledge the thromboembolism as peripheral artery embolism, TIA and ischaemic stroke, and bleeding as gastrointestinal, urinary tract and airways as well as intracranial. These differences may also lead to error. Statistical differences at p<0.05 are assumed if 95% confidence intervals fail to overlap, but these intervals are defined by power in terms of number of events and number of patients (in the Danish cohort 11 , 38,546 patients had a HAS-BLED score >3, whereas 93,826 (2.4x more) had a HAS-BLED score <2). This may explain why, at a CHADS 2 score of 0, a 56% better NCB for edoxaban 30 mg at HAS-BLED score >3 compared to edoxaban 60 mg is not significant (table 4) , whereas a smaller 31% at CHADS 2 score of 1 and 26% at CHA 2 DS 2 VASc score of 2-9 of the respective better NCB for the 30 mg dose at HAS-BLED
14 score >2 is statistically significant. Accordingly, we note the caveat that wide (and so overlapping) confident intervals consequent to low power may give rise to false negatives.
Finally, we note that Danish cohort was studied between 1997 and 2008, whilst the ENGAGE-AF trial was conducted between 2008 and 2010. Accordingly, differences in general clinical practice and different drugs and other treatments over more than a decade may also lead to error or residual confounding. A further limitation is that the results from the Engage AF-TIMI 48 trial of edoxaban 10 may not reflect the real world, and that one might expect that the risk of ICH would be greater. In addressing this point our sensitivity analysis based on the likelihood that the rate of ICH were twice that observed in the trial, and that the rate of stroke and systemic embolism were lowered by 50% translated, to no profound changes in the extent to which either doses of edoxaban are or are not preferable to warfarin.
In conclusion, based on this modelling analysis of NCB, edoxaban is preferable over warfarin for 'all comers' with AF, with the two edoxaban doses apparently bringing the same favourable NCB compared to warfarin. However, degree of benefit differs according to CHADS 2 , CHA 2 DS 2 -VASc and HAS-BLED scores. At CHA 2 DS 2 -VASc score ≥2, both edoxaban doses were superior to warfarin, but compared to no treatment, the 60 mg dose had a better NCB than the 30mg dose or warfarin. Assessment of the patient's risk profile may allow a more tailored and efficient approach to stroke prevention. is calculated as annualised (stroke and systemic embolism rate off treatment -stroke and systemic embolism rate on treatment ) -1.5 x (ICH rate on treatment -ICH rate off treatment ) Net clinical benefit (NCB) = events prevented per 100 patient-years (95% confidence interval) of edoxaban is calculated as annualised NCB on warfarin 12 -[1-relative risk of stroke and systemic embolism for edoxaban 10 x stroke and systemic embolism rate on 
